Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.
Related Articles
Zolbetuximab Approval Paves Way for Precision Medicine in Gastric and GEJ Adenocarcinoma
Cindy M. Pabon, MD, discusses efforts to improve patient outcomes in gastric/GEJ cancer through the development of effective biomarker–targeted therapies.
Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.
The Clinical Utility of Genetic Risk Scores in Chronic Lymphocytic Leukemia
Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic leukemia.
An Assortment of Journal Abstracts to Enhance Oncology Care : Oncology Times
An abstract is unavailable.
Innovative ctDNA Testing Drives Progress in NSCLC Research
The TROPION-Lung12 trial uses a circulating tumor DNA assay to preoperatively screen patients with non–small cell lung cancer for eligibility in post-surgical adjuvant treatment regimens.
Toripalimab Plus Chemo: A First-Line Option for ES-SCLC? – Oncology Nurse Advisor
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed…
A Quick Start Guide to Cancer Data Science for Clinical Oncology | CBIIT
Whether you are in the data science field, interested in developing computational solutions for clinical oncology, or a clinical researcher, we’ve curated a list of…
Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis
Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.